Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha

American Journal of Medicine

Volumn 101, Issue 5, 1996, Pages 482-487

  Roti, Elio ^a   Minelli, Roberta ^a   Giuberti, Tiziana ^a   Marchelli, Silvia ^a   Schianchi, Claudia ^a   Gardini, Eliana ^a   Salvi, Mario ^a   Fiaccadori, Franco ^a   Ugolotti, Giorgio ^a   Neri, Tauro M ^a   Braverman, Lewis E ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; IODINE; RECOMBINANT PROTEIN; THYROID HORMONE;

ADULT; ARTICLE; AUTOIMMUNITY; BLOOD; CHRONIC HEPATITIS; DRUG EFFECT; FEMALE; HEPATITIS C; HUMAN; IMMUNOLOGY; MALE; METABOLISM; THYROID FUNCTION TEST; THYROID GLAND;

ADULT; ANTIVIRAL AGENTS; AUTOIMMUNITY; FEMALE; HEPATITIS C; HEPATITIS, CHRONIC; HUMANS; INTERFERON-ALPHA; IODINE; MALE; RECOMBINANT PROTEINS; THYROID FUNCTION TESTS; THYROID GLAND; THYROID HORMONES;

EID: 0030279780     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(96)00259-8     Document Type: Article

References (45)

1. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Safety. 1994;10:115-150.
2. Fentiman IS, Thomas BS, Balkwill FR, et al. Primary hypothyroidism associated with interferon therapy of breast cancer. Lancet. 1985;1:1166.
3. Burman P, Totterman TH, Oberg K, Karlsson FA. Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. J Clin Endocrinol Metab. 1986;63:1086-1090.
4. Fentiman IS, Balkwill FR, Thomas BS, et al. An autoimmune etiology for hypothyroidism following interferon therapy for breast cancer. Eur J Cancer Clin Oncol. 1988;24:1299-1303.
5. Schultz M, Muller R, von zur Muhlen A, Brabant G. Induction of hyperthyroidism by interferon-alpha-2b. Lancet. 1989;1:1452.
6. Conlon KC, Urba WJ, Smith JW, et al. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer. 1990;65:2237-2242.
7. Pichert G, Jost LM, Zoeli L, et al. Thyroiditis after treatment with interleukin-2 and interferon-alpha-2a. Br J Cancer. 1992;62:100-104.
8. Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med. 1991;115:18-83.
9. Berris B, Feinman SV. Thyroid dysfunction and liver injury following alpha-interferon treatment of chronic viral hepatitis. Dig Dis Sci. 1991;36:1657-1660.
10. Lisker-Melman M, Di Bisceglie AM, Usala SJ, et al. Development of thyroid disease during therapy of chronic viral hepatitis with interferon-alpha. Gastroenterology. 1992;102:2155-160.
11. Gisslinger H, Gilly B, Wolosczuk W, et al. Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha. Clin Exp Immunol. 1992;90:363-367.
12. Vassilpolou-Sellin R, Selia A, Dexeus FH, et al. Acute thyroid dysfunction (thyroiditis) after therapy with interleukin-2. Horm Metab Res. 1992;24:434-438.
13. Taniguchi Y, Murakami T, Nakanishi K, et al. Two cases of hypothyroidism associated with alpha-interferon therapy. Intern Med. 1992;31:373-376.
14. Kamikubo K, Takami R, Suwa T, et al. Case report: silent thyroiditis developed during alpha-interferon therapy. Am J Med Sci. 1993;306:174-176.
15. Sauter NP, Atkins MB, Mier JW, Lechan RM. Transient thyrotoxicosis and persistent hypothyroidism due to acute autoimmune thyroiditis after interleukin-2 and interferon-alpha therapy for metastatic carcinoma: a case report. Am J Med. 1992;92:441-444.
16. Tran A, Quaranta JF, Benzaken S, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology. 1993;18:253-257.
17. Watanabe U, Hashimoto E, Hisamitsu T, et al. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am J Gastroenterol. 1994;89:399-403.
18. Imagawa A, ltoh N, Hanafusa T, et al. Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis. J Clin Endocrinol Metab. 1996;80:922-926.
19. Yamazaki K, Kanaji Y, Shizume K, et al. Reversible inhibition by interferons alpha and beta of 125I incorporation and thyroid hormone release by human thyroid follicles in vitro. J Clin Endocrinol Metab. 1993;77:1439-1441.
20. Sato K, Satoh T, Shizume K, et al. Inhibition of 125I organification and thyroid hormone release by interleukin-1, tumor necrosis factor-alpha, and interferon-gamma in human thyrocytes in suspension culture. J Clin Endocrinol Metab. 1990;70:1735-1743.
21. Cavalieri RR. Quantitative in vivo tests. In: Braverman LE, Utiger R, eds. Werner and Ingbar's The Thyroid. 5th ed. Philadelphia: JB Lippincott; 1986:445.
22. Galen RS, Gambino SR. Beyond Normality: The Predictive Value and Efficiency of Medical Diagnoses. New York: John Wiley & Sons; 1975.
23. Marcellin P, Pouteau M, Benhamou JP. Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. J Hepatol. 1995;22:364-369.
24. Preziati D, La Rosa L, Covini G, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol. 1995;132:587-593.
25. Barreca T, Picciotto A, Franceschini R, et al. Long term therapy with recombinant interferon alpha-2b in patients with chronic hepatitis C: effects on thyroid function and autoantibodies. J Biol Regul Homeost Agents. 1993;7: 58-62.
26. Weetman AP, McGregor AM. Autoimmune thyroid disease: further developments in our understanding. Endocr Rev. 1994;15:788-830.
27. Tran A, Benzaken S, Braun HB, et al. Anti-GOR and anti-thyroid autoantibodies in patients with chronic hepatitis C. Clin Immunol Immunopathol. 1995;77:127-130.
28. Mayet WJ, Hess G, Gerken G, et al. Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology. 1989;10:24-28.
29. Fonseca V, Thomas M, Dusheiko G. Thyrotropin receptor antibodies following treatment with recombinant alpha-interferon in patients with hepatitis. Acta Endocrinol (Copenh). 1991;125:491-493.
30. Papo T, Oksenhendler E, Izembart M, et al. Antithyroid hormone antibodies induced by interferon-alpha. J Clin Endocrinol Metab. 1992;75: 1484-1486.
31. Todd I, Pujol-Borrell R, Hammond L, et al. Interferon-gamma induces HLA-DR expression by thyroid epithelium. Clin Exp Immunol. 1985;61:265-273.
32. Guerin V, Todd I, Hammondi LJ, Bottazzo GF. Suppression of HLA class II expression on thyrocytes by interferon-alpha 1. Clin Exp Immunol. 1990;79:341-345.
33. Stanbury JB. Inherited metabolic disorders of the thyroid system. In: Braverman LE, Utiger RD, eds. Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text. Philadelphia: JB Lippincott; 1991:934-941.
34. Braverman LE, Ingbar SH, Vagenikis AG, et al. Enhanced susceptibility to iodide myxedema in patients with Hashimoto's disease. J Clin Endocrinol Metab. 1971;32:515-521.
35. Roti E, Minelli R, Gardini E, et al. Impaired intrathyroidal iodine organification and iodine-induced hypothyroidism in euthyroid women with a previous episode of postpartum thyroiditis. J Clin Endocrinol Metab. 1991;73:958-963.
36. Braverman LE, Woeber KA, Ingbar SH. The induction of myxedema by iodide in patients euthyroid after radioiodine or surgical treatment of diffuse toxic goiter. NEJM. 1969;281:816-821.
37. 131I-treated and untreated hyperthyroidism. J Clin Endocrinol Metab. 1972;34:332-338.
38. Roti E, Gardini E, Minelli R, et al. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism. J Clin Endocrinol Metab. 1993; 76:928-932.
39. Roti E, Minelli R, Gardini E, et al. Iodine-induced hypothyroidism in euthyroid subjects with a previous episode of subacute thyroiditis. J Clin Endocrinol Metab. 1990;70:1581-1585.
40. Roti E, Minelli R, Gardini E, et al. Iodine induced subclinical hypothyroidism in euthyroid subjects with a previous episode of amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab. 1992;75:1273-1277.
41. Clark OH, Cavalieri PR, Moser C, Ingbar SH. Iodine induced hypothyroidism in patients after thyroid resection. Eur J Clin Invest. 1990;20:573-580.
42. Roti E, Minelli R, Gardini E, et al. The iodine perchlorate discharge test before and after one year of methimazole treatment of hyperthyroid Graves' disease. J Clin Endocrinol Metab. 1994;78:795-799.
43. Kung AWC, Ma L, Lau KS. The role of interferon-gamma in lymphocytic thyroiditis: its functional and pathological effect on human thyrocytes in culture. Clin Exp Immunol. 1992;87:261-265.
44. Asakawa H, Hanafusa T, Kobayashi T, et al. Interferon-gamma reduces the thyroid peroxidase content of cultured human thyrocytes and inhibits its increase induced by thyrotropin. J Clin Endocrinol Metab. 1992;74: 1331-1335.
45. Tang KT, Braverman LE, DeVito WJ. Tumor necrosis factor-alpha and interferon-gamma modulate gene expression of type I 5′-deiodinase, thyroid peroxidase, and thyroglobulin in FRTL-5 rat thyroid cells. Endocrinology. 1995;136:861-868.